日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The ESSENCE of hope: what semaglutide's Food and Drug Administration approval means for metabolic dysfunction-associated steatohepatitis

希望的本质:司美格鲁肽获得美国食品药品监督管理局批准对代谢功能障碍相关性脂肪性肝炎意味着什么

Alamgir, Mariam; Sohal, Aalam; Kowdley, Kris V

Association of Components of Metabolic Syndrome and the Progression of Nonalcoholic Fatty Liver Disease

代谢综合征各组分与非酒精性脂肪肝疾病进展的关联

Le, Phuc; Tatar, Moosa; Rothberg, Michael B; Wilson, Laura A; Allende, Daniela; Diehl, Anna Mae; Loomba, Rohit; Chalasani, Naga; Neuschwander-Tetri, Brent A; Kowdley, Kris; Sanyal, Arun J; Tonascia, James; Dasarathy, Srinivasan

Novel MicroRNA biomarkers revealed in the serum and bile of thioacetamide induced cholangiocarcinoma

硫代乙酰胺诱导的胆管癌患者血清和胆汁中发现的新型microRNA生物标志物

Chen, Weisheng; Herring, Brendon R; Watts, Jasmine; MacVicar, Caroline; Crossman, David; Kumar, Nilesh; Mukhtar, M Shahid; Rocha, Flavio; Kowdley, Kris V; Rose, J Bart

Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVE

基线碱性磷酸酶水平影响原发性胆汁性胆管炎的治疗反应率:ELATIVE 研究探讨 Elafibranor 的疗效

Levy, Cynthia; Bowlus, Christopher L; Lawitz, Eric; Antunes, Nuno; Miller, Benjamin; Shu, Jianfen; Zein, Claudia O; Kowdley, Kris V

Efimosfermin for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): Mechanism of Action, Clinical Development and Emerging Therapeutic Potential

Efimosfermin治疗代谢功能障碍相关性脂肪性肝炎(MASH):作用机制、临床开发及新兴治疗潜力

Alamgir, Mariam; Sohal, Aalam; Kowdley, Kris V

Economic Burden of Primary Biliary Cholangitis by Line of Therapy in the United States

美国原发性胆汁性胆管炎不同治疗方案的经济负担

Kumar, Sonal; Shamseddine, Nisreen; Yang, Hongbo; Zhang, Su; Ye, Dongni; Seshasayee, Shravanthi; Chen, Jingyi; Kowdley, Kris V

Drug re-purposing to improve outcomes in the management of prostate cancer - aims, outcome measures and design of current phase III trials

药物再利用以改善前列腺癌治疗效果——当前III期试验的目标、结果指标和设计

Gilbert, Duncan C; Langley, Ruth E; Ayadi, Dami; Berhanu, Mannab; Hemanth, Lakshmi Kowdley; Kwon, Seunghee; Abdallah, Hossameldin; Meade, Angela; Clarke, Noel; Gillessen, Silke; James, Nicholas; Bouche, Gauthier; Parmar, Mahesh; Nankivell, Matthew; Murphy, Laura

TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial

TERN-501 单药治疗及与 TERN-101 联合治疗代谢功能障碍相关性脂肪性肝炎:随机 2a 期 DUET 试验

Noureddin, Mazen; Alkhouri, Naim; Lawitz, Eric J; Kowdley, Kris V; Loomba, Rohit; Lee, Lois; Jones, Christopher; Schlegel, Amnon; Marmon, Tonya; Anderson, Kacey; Li, Yizhao; Quirk, Erin; Harrison, Stephen A

Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design

奥贝胆酸治疗原发性胆汁性胆管炎的真实世界肝脏结局(HEROES):一项试验模拟研究设计

Brookhart, M Alan; Mayne, Tracy J; Coombs, Charles; Breskin, Alexander; Ness, Erik; Bessonova, Leona; Chu, Yucheng Julia; Li, Jing; Fried, Michael W; Hansen, Bettina E; Kowdley, Kris V; Jones, David; Mells, George; Trivedi, Palak J; Hiu, Shaun; Kareithi, Dorcas N; Wason, James; Smith, Rachel; Seeger, John D; Hirschfield, Gideon M

Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study

经活检证实的代谢功能障碍相关脂肪肝患者中,糖尿病患者与非糖尿病患者的肝脏硬度进展情况:一项前瞻性多中心研究

Huang, Daniel Q; Wilson, Laura A; Behling, Cynthia; Amangurbanova, Maral; Kleiner, David E; Kowdley, Kris V; Dasarathy, Srinivasan; Terrault, Norah A; Diehl, Anna Mae; Chalasani, Naga; Neuschwander-Tetri, Brent A; Sanyal, Arun J; Tonascia, James; Loomba, Rohit